Developing and validating a computed tomography radiomics strategy to predict lymph node metastasis in pancreatic cancer

Table 1 Demographic characteristics of pancreatic cancer patients with or without lymph node metastasis, n (%)/mean ± SD/median (25^th-75^th percentiles)

Variables	PC with LNM (n = 61)	PC without LNM (n = 107)	P value
Age (years)	63.65 ± 10.95	61.72 ± 10.66	0.2141
Gender			0.5012
Male	43 (70.5)	70 (65.4)
Female	18 (29.5)	37 (34.6)
Clinical symptoms
Abdominal pain	45 (73.8)	69 (64.5)	0.2152
Abdominal bloating or diarrhea	12 (19.7)	19 (17.8)	0.7582
Yellow urine or icterus	18 (29.5)	30(28.0)	0.8392
Marasmus	9 (14.8)	14 (13.1)	0.7622
Asymptomatic	22 (36.1)	31 (29.0)	0.3412
Tumor markers
CA125	22.80 (15.60-39.40)	20.50 (3.20-34.70)	0.3253
CA199	205.75 (43.90-954.8)	178.96 (39.98-832.67)	0.1053
CEA	4.59 (2.68-6.02)	3.99 (2.44-5.80)	0.4323
AFP	2.95 (2.11-4.54)	2.65 (1.85-4.04)	0.6653

¹Calculated with a t-test.

²Calculated with a Fisher’s exact test or an χ² test.

³Calculated with Mann-Whitney U test.

LNM: Lymph node metastasis; PC: Pancreatic cancer; CEA: Carcinoembryonic antigen; AFP: Alpha-fetoprotein.

Table 2 Diagnostic performance of Radscore model for prediction of lymph node metastasis in pancreatic cancer patients using receiver operating characteristic analysis

Group	Model	AUC (95%CI)	Accuracy	Sensitivity	Specificity	PPV	NPV
Training set	Radscore_A	0.92 (0.87-0.97)	86.7%	89.8%	84.9%	77.2%	93.6%
	Radscore_P	0.94 (0.90-0.98)	91.1%	85.7%	94.2%	89.4%	92.0%
Test set	Radscore_A	0.86 (0.73-1.00)	78.8%	91.7%	71.4%	64.7%	93.8%
	Radscore_P	0.93 (0.83-1.00)	87.9%	66.7%	100.0%	100.0%	84.0%

AUC: Area under the curve; PPV: Positive predictive value; NPV: Negative predictive value.